Technology
Health
Biotechnology
Cytokinetics
$10.059876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$10.05
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.48 (5.02%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Cytokinetics and other stocks, options, ETFs, and crypto commission-free!
About
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). Read More The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
Employees
130
Headquarters
South San Francisco, California
Founded
1997
Market Cap
557.28M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
424.04K
High Today
$10.38
Low Today
$9.62
Open Price
$9.67
Volume
223.72K
52 Week High
$11.33
52 Week Low
$5.75
Collections
Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
US
North America
News
Seeking AlphaMay 9
Cytokinetics, Incorporated. CEO Robert Blum on Q1 2019 Results - Earnings Call Transcript
Cytokinetics, Incorporated. (NASDAQ:CYTK) Q1 2019 Results Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants Diane Weiser - Vice President, Corporate Communications and Investor Relations Robert Blum - President and Chief Executive Officer Fady Malik - Executive Vice President, Research and Development Andy Wolff - Senior Vice President and Chief Medical Officer Pete Roddy - Senior Vice President and Chief Accounting Officer Ching Jaw - Senior Vice President and Chief Financial Offi...
Yahoo FinanceMay 9
Cytokinetics Reports Q1 Loss, Tops Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of -14.89% and 36.41%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Yahoo FinanceMay 9
Cytokinetics: 1Q Earnings Snapshot
SOUTH SAN FRANCISCO, Calif. (AP) _ Cytokinetics Inc. (CYTK) on Thursday reported a loss of $29.4 million in its first quarter. The South San Francisco, California-based company said it had a loss of 54 cents per share. The biopharmaceutical company posted revenue of $8.5 million in the period. Cytokinetics shares have increased 43% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $9.03, a climb of slightly more than 1% in the last 12 months. _____ This story was ...
Price Paid on Robinhood
6% Higher
Right Now
52 Week Low
$5.75
Average Price Paid
$9.48
52 Week High
$11.33
Earnings
-$0.75
-$0.63
-$0.52
-$0.40
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Jul 25, After Hours